News Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
7.24 ^USD	-0.82%		+2.84%	+59.12%

Mar. 19	North American Morning Briefing : Stock Futures -2-	DJ
Mar. 14	Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Larimar: Q4 Earnings Snapshot	Mar. 14	AQ
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development	Mar. 14	AQ
Sector Update: Health Care Stocks Gain Premarket Tuesday	Mar. 12	MT
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Larimar Therapeutics Doses 1st Patient in Study of Movement Disorder Treatment	Mar. 11	MT
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia	Mar. 11	AQ
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia	Mar. 11	CI
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference	Mar. 06	AQ
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	Feb. 16	AQ
Top Midday Gainers	Feb. 14	MT
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock	Feb. 14	AQ
Larimar Therapeutics Starts Public Offering of Common Shares, Pre-Funded Warrants	Feb. 14	MT
Larimar Therapeutics Announces Proposed Underwritten Public Offering	Feb. 13	AQ
Top Midday Gainers	Feb. 13	MT
Guggenheim Adjusts Price Target on Larimar Therapeutics to $25 From $14, Maintains Buy Rating	Feb. 13	MT
Citigroup Adjusts Price Target on Larimar Therapeutics to $10 From $4.50, Maintains Buy Rating	Feb. 13	MT
JMP Securities Adjusts Price Target on Larimar Therapeutics to $25 From $17, Maintains Market Outperform Rating	Feb. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Summary

Filters